Esperion Therapeutics (ESPR)
(Real Time Quote from BATS)
$1.98 USD
+0.08 (4.21%)
Updated Apr 29, 2024 12:18 PM ET
3-Hold of 5 3
F Value A Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ESPR 1.98 +0.08(4.21%)
Will ESPR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ESPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ESPR
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
ESPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?
Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics
5 Small Drug Stocks to Buy From a Rebounding Industry
Other News for ESPR
Esperion to Participate in Upcoming May Investor Conferences
Tourlite Capital Q1 2024 Investor Letter
Esperion to Report First Quarter 2024 Financial Results on May 7
Applied Digital Reports Downbeat Results, Joins Nurix Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session